Next Article in Journal
Single-Cell Heterogeneity of Epigenetic Factor Regulation Deciphers Alteration of RNA Metabolism During Proliferative SHH-Medulloblastoma
Previous Article in Journal
Prognostic Impact of Postoperative Systemic Immune-Inflammation Index Changes in Epithelial Ovarian Cancer
Previous Article in Special Issue
Hypo-Fractionated Stereotactic Radiosurgery for the Management of Brain Metastases
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

High-Dose Stereotactic Re-Irradiation of Recurrent High-Grade Gliomas: Clinical Outcome and Experience with AI-Based Target Volume Simulation

1
Department of Neurosurgery, Charité Universitaetsmedizin Berlin, 10117 Berlin, Germany
2
Charité CyberKnife Center, Charité Universitaetsmedizin Berlin, 10117 Berlin, Germany
3
Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
4
Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors also contributed equally to this work.
Cancers 2025, 17(21), 3423; https://doi.org/10.3390/cancers17213423 (registering DOI)
Submission received: 5 September 2025 / Revised: 16 October 2025 / Accepted: 17 October 2025 / Published: 24 October 2025
(This article belongs to the Special Issue Radiosurgery for Brain Tumors)

Abstract

Background/Objectives: Despite multimodal therapeutic concepts, treatment of recurrent malignant gliomas remains challenging. Stereotactic radiosurgery (SRS) may be a possible safe and effective non-invasive salvage treatment. In this study, we aim to investigate the SRS treatment outcomes using partly 18F-Fluorethylthyrosine (FET)-PET-imaging sequences for SRS treatment planning focusing on overall survival, event-free survival, and the incidence and factors influencing radiation necrosis (RN) occurrence. Additionally, we evaluated the potential application of AI-based tumor segmentation. Methods: We conducted a retrospective analysis of patients with recurrent malignant glioma treated with single-fraction or hypofractionated SRS at our institution. The outcomes assessed included local control, overall survival (OS), and local event-free survival (LEFS, defined as the interval until tumor recurrence or the onset of RN). We also performed a simulation analysis to assess the potential of AI-based tumor segmentation. Results: The study included 27 patients with a median age of 57 years and 41 lesions. The median OS post-SRS was 9.6 months and an LEFS of 5.2 months. Factors positively influencing OS and LEFS included the gross tumor volume (GTV) of the lesions before SRS therapy, presence of an IDH mutation, and lomustine treatment post-SRS. The incidence of RN post-SRS was 31.7%. RN was confirmed histopathologically in 15.4%, based on MRI in 46.2% and by FET-PET in 38.5% of lesions. In a simulation analysis, AI-based tumor segmentation reliably delineated all lesions, requiring only minimal manual adjustments to define target volumes. Conclusions: High-dose SRS is a feasible salvage treatment for small-volume recurrent high-grade gliomas, achieving local control and survival outcomes comparable to other re-irradiation strategies. IDH mutation, smaller tumor volume, and lomustine therapy were associated with improved survival. RN occurred frequently, particularly in periventricular lesions. AI-based tumor segmentation showed promise in well-defined satellite recurrences, but remains limited in cavity-adjacent lesions, underlining the need for expert review and 18FET-PET imaging.
Keywords: radiosurgery; high-grade glioma; glioblastoma; radionecrosis; 18-FET-PET; AI-based tumor segmentation radiosurgery; high-grade glioma; glioblastoma; radionecrosis; 18-FET-PET; AI-based tumor segmentation

Share and Cite

MDPI and ACS Style

Früh, A.; Loebel, F.; Bodnar, B.; Kilian, L.; Misch, M.; Kalinauskaite, G.; Kluge, A.; Eitner, C.; Onken, J.; Rubarth, K.; et al. High-Dose Stereotactic Re-Irradiation of Recurrent High-Grade Gliomas: Clinical Outcome and Experience with AI-Based Target Volume Simulation. Cancers 2025, 17, 3423. https://doi.org/10.3390/cancers17213423

AMA Style

Früh A, Loebel F, Bodnar B, Kilian L, Misch M, Kalinauskaite G, Kluge A, Eitner C, Onken J, Rubarth K, et al. High-Dose Stereotactic Re-Irradiation of Recurrent High-Grade Gliomas: Clinical Outcome and Experience with AI-Based Target Volume Simulation. Cancers. 2025; 17(21):3423. https://doi.org/10.3390/cancers17213423

Chicago/Turabian Style

Früh, Anton, Franziska Loebel, Bohdan Bodnar, Larissa Kilian, Martin Misch, Goda Kalinauskaite, Anne Kluge, Chiara Eitner, Julia Onken, Kerstin Rubarth, and et al. 2025. "High-Dose Stereotactic Re-Irradiation of Recurrent High-Grade Gliomas: Clinical Outcome and Experience with AI-Based Target Volume Simulation" Cancers 17, no. 21: 3423. https://doi.org/10.3390/cancers17213423

APA Style

Früh, A., Loebel, F., Bodnar, B., Kilian, L., Misch, M., Kalinauskaite, G., Kluge, A., Eitner, C., Onken, J., Rubarth, K., Zips, D., Vajkoczy, P., Senger, C., & Acker, G. (2025). High-Dose Stereotactic Re-Irradiation of Recurrent High-Grade Gliomas: Clinical Outcome and Experience with AI-Based Target Volume Simulation. Cancers, 17(21), 3423. https://doi.org/10.3390/cancers17213423

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop